多発性硬化症治療薬の世界市場レポート 2024

多発性硬化症治療薬の市場規模は、今後数年間で大幅に成長すると予想されます。 2028年には11.1%の年間複合成長率（CAGR）で479億7,000万米ドルに成長すると予想されます。予測される拡大は、臨床試験へのアクセスの強化、標的療法、予防ヘルスケアの重視の高まり、バイオシミラーの需要の増加、世界市場への浸透の拡大、併用療法の統合によって促進されています。この期間中に予想される主要な動向には、免疫調節薬の開発、徐放性製剤、患者中心のケアアプローチ、継続的な医薬品革新、経口および点滴治療の進歩が含まれます。

政府および非政府組織は、多発性硬化症治療薬市場の成長に大きく貢献しています。彼らは、多発性硬化症（MS）に苦しむ人々の生活の質の向上を目的としたさまざまなプログラムや取り組みを支援しています。その一例は、アルバータ州政府とカナダ経済開発貿易観光省によるカナダのMS前向きコホート研究（CanProCo）への100万米ドルの共同投資です。複数の組織の支援を受けたこの取り組みでは、調査とイノベーションのために1,000万米ドルが集まり、カナダの分野を超えた50人近くのMS研究者が団結しました。これらの団体からの財政的支援により、多発性硬化症治療薬市場の拡大が促進されます。

多発性硬化症の有病率の拡大は、多発性硬化症治療薬市場の成長を推進する極めて重要な要因となっています。 MSは中枢神経系に影響を与える自己免疫疾患であり、症状管理と病気の進行のために医薬品による介入が必要です。 2023年5月のペース病院の記事では、世界のMS患者数は280万人で、その割合は10万人当たり35.9人、報告国75カ国で年間発生率は10万人当たり2.1人であると強調しました。この病気は通常32歳前後の人が罹患し、女性の罹患率が高くなります。この有病率の増加は、多発性硬化症治療薬市場の拡大を促進すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の多発性硬化症治療薬市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 免疫調節剤
• 免疫抑制剤
• インターフェロン
• その他の薬剤クラス
• 世界の多発性硬化症治療薬市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院薬局
• 小売薬局
• オンラインストア
• 世界の多発性硬化症治療薬市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 経口薬
• 非経口薬

第7章 地域および国の分析

• 世界の多発性硬化症治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の多発性硬化症治療薬市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 多発性硬化症治療薬市場の競合情勢
• 多発性硬化症治療薬市場の企業プロファイル
  • Biogen Inc.
  • Novartis International AG
  • F. Hoffmann-La Roche Ltd.
  • Bayer HealthCare LLC
  • Pfizer Inc

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

Multiple sclerosis drugs, referred to as disease-modifying treatments, aim to halt the progression of disability and the occurrence of disease relapses associated with the condition. These medications work by targeting a protein present on the surface of immune cells, leading to a reduction in the number of white blood cells. This reduction helps prevent relapses in multiple sclerosis by potentially diminishing the white blood cells' tendency to cause nerve injury.

The primary drug classes for multiple sclerosis treatment include immunomodulators, immunosuppressants, interferons, and others. Immunomodulators specifically target pathways involved in treating multiple myeloma and certain other cancers. These drugs can be administered through various routes, including oral and parenteral methods, and are distributed through hospital pharmacies, retail pharmacies, and online platforms.

The multiple sclerosis drugs market research report is one of a series of new reports from The Business Research Company that provides multiple sclerosis drugs market statistics, including multiple sclerosis drugs industry global market size, regional shares, competitors with a multiple sclerosis drugs market share, detailed multiple sclerosis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the multiple sclerosis drugs industry. This multiple sclerosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The multiple sclerosis drugs market size has grown strongly in recent years. It will grow from $29.66 billion in 2023 to $31.5 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. Historical growth in the field of multiple sclerosis treatment can be attributed to several factors, including the increasing prevalence of multiple sclerosis, a significant unmet medical need for effective treatments, heightened investments from pharmaceutical companies dedicated to research and development, and a growing awareness and understanding of multiple sclerosis within the medical community and among the general population.

The multiple sclerosis drugs market size is expected to see strongly grown in the next few years. It will grow to $47.97 billion in 2028 at a compound annual growth rate (CAGR) of 11.1%. The projected expansion is fueled by enhanced access to clinical trials, targeted therapies, a rising emphasis on preventive healthcare, increased demand for biosimilars, wider global market penetration, and the integration of combination therapies. Key trends expected during this period encompass the development of immunomodulatory drugs, extended-release formulations, patient-centered care approaches, continual drug innovation, and the advancement of oral and infusion treatments.

Government and non-government organizations contribute significantly to the growth of the multiple sclerosis drugs market. They support various programs and initiatives aimed at improving the quality of life for those affected by multiple sclerosis (MS). An example is the joint investment of $1 million by the government of Alberta and Canada's Department of Economic Development, Trade, and Tourism for the Canadian Prospective Cohort Study on MS (CanProCo). This initiative, supported by multiple organizations, gathered $10 million for research and innovations, uniting nearly 50 MS researchers across disciplines in Canada. Financial backing from these entities drives the expansion of the multiple sclerosis drugs market.

The escalating prevalence of multiple sclerosis stands as a pivotal factor propelling the growth of the multiple sclerosis drug market. MS, an autoimmune disease impacting the central nervous system, requires pharmaceutical intervention for symptom management and disease progression. An article from Pace Hospitals in May 2023 highlighted a global MS patient count of 2.8 million, at a rate of 35.9 per 100,000 individuals, with an annual incidence of 2.1 cases per 100,000 people across 75 reporting countries. The disease typically affects individuals around the age of 32 and shows a higher prevalence among females. This increasing prevalence is set to drive the expansion of the multiple sclerosis drug market.

Companies are intensifying efforts to introduce new products within the multiple sclerosis drug market to cater to the surging demand. Given the lifelong treatment nature of MS, the overall cost of patient care is substantial. To address this, companies are focusing on developing specific drugs tailored for managing multiple sclerosis. Notably, the FDA approved Novartis' Mayzent (siponimod) and EMD Serono's Mavenclad (cladribine) for treating relapsing-remitting and active secondary progressive multiple sclerosis. These oral drugs aim to provide more effective treatment options.

Major companies in the multiple sclerosis drug market are prioritizing innovation to gain a competitive advantage. They are introducing novel products such as the Aidaptus auto-injector platform to enhance drug delivery. For instance, Owen Mumford, a UK-based medical device manufacturer, launched the Aidaptus auto-injector platform in September 2021. This platform simplifies operations and accommodates diverse drug formulations, including those for multiple sclerosis, using a dual-purpose auto-injector with a versatile design capable of administering various prefilled glass syringes.

In 2019, Bristol-Myers Squibb, a US-based pharmaceutical firm, made a $74 billion acquisition of Celgene. This strategic move is geared toward broadening Bristol-Myers Squibb's product range by leveraging Celgene's current product lineup and tapping into its technical expertise and pipeline support. Among Celgene's pipeline drugs is Ozanimod, currently undergoing phase III clinical trials seeking FDA approval for the treatment of relapsing multiple sclerosis. Celgene, also headquartered in the US, specializes in the development and marketing of medications for conditions like cancer and inflammatory diseases, including multiple sclerosis.

Major companies operating in the multiple sclerosis drugs market include Biogen Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Bayer HealthCare LLC, Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC, Acorda Therapeutics Inc., Actelion Pharmaceuticals Ltd., EMD Serono Inc., AbbVie Inc., Bayer Schering Pharma AG, CinnoVex, Rebif, Bristol-Myers Squibb Company, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Mylan N.V., Opexa Therapeutics Inc., Receptos Inc., Synthon Pharmaceuticals Inc., TG Therapeutics Inc., Alexion Pharmaceuticals Inc., Alkermes PLC, Amgen Inc., Apitope Technology (Bristol) Ltd., Atara Biotherapeutics Inc., Celgene Corporation, Genzyme Corporation

North America was the largest region in the global multiple sclerosis drug market in 2023. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple sclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the multiple sclerosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The multiple sclerosis drug market consists of sales of lemtrada, novantrone, ocrevus, and tysabri. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Multiple Sclerosis Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on multiple sclerosis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for multiple sclerosis drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The multiple sclerosis drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Drug Class: Immunomodulators; Immunosuppressants; Interferons; Other Drug Classes
• 2) By Distribution Channels: Hospital Pharmacy; Retail Pharmacy; Online Stores
• 3) By Route Of Administration: Oral Drugs; Parenteral Drugs
• Companies Mentioned: Biogen Inc.; Novartis International AG; F. Hoffmann-La Roche Ltd.; Bayer HealthCare LLC; Pfizer Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Multiple Sclerosis Drugs Market Characteristics

3. Multiple Sclerosis Drugs Market Trends And Strategies

4. Multiple Sclerosis Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Multiple Sclerosis Drugs Market Size and Growth

• 5.1. Global Multiple Sclerosis Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Multiple Sclerosis Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Multiple Sclerosis Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Multiple Sclerosis Drugs Market Segmentation

• 6.1. Global Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Immunomodulators
• Immunosuppressants
• Interferons
• Other Drug Classes
• 6.2. Global Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Stores
• 6.3. Global Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oral Drugs
• Parenteral Drugs

7. Multiple Sclerosis Drugs Market Regional And Country Analysis

• 7.1. Global Multiple Sclerosis Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Multiple Sclerosis Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Multiple Sclerosis Drugs Market

• 8.1. Asia-Pacific Multiple Sclerosis Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Multiple Sclerosis Drugs Market

• 9.1. China Multiple Sclerosis Drugs Market Overview
• 9.2. China Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Multiple Sclerosis Drugs Market

• 10.1. India Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Multiple Sclerosis Drugs Market

• 11.1. Japan Multiple Sclerosis Drugs Market Overview
• 11.2. Japan Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Multiple Sclerosis Drugs Market

• 12.1. Australia Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Multiple Sclerosis Drugs Market

• 13.1. Indonesia Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Multiple Sclerosis Drugs Market

• 14.1. South Korea Multiple Sclerosis Drugs Market Overview
• 14.2. South Korea Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Multiple Sclerosis Drugs Market

• 15.1. Western Europe Multiple Sclerosis Drugs Market Overview
• 15.2. Western Europe Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Multiple Sclerosis Drugs Market

• 16.1. UK Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Multiple Sclerosis Drugs Market

• 17.1. Germany Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Multiple Sclerosis Drugs Market

• 18.1. France Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Multiple Sclerosis Drugs Market

• 19.1. Italy Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Multiple Sclerosis Drugs Market

• 20.1. Spain Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Multiple Sclerosis Drugs Market

• 21.1. Eastern Europe Multiple Sclerosis Drugs Market Overview
• 21.2. Eastern Europe Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Multiple Sclerosis Drugs Market

• 22.1. Russia Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Multiple Sclerosis Drugs Market

• 23.1. North America Multiple Sclerosis Drugs Market Overview
• 23.2. North America Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Multiple Sclerosis Drugs Market

• 24.1. USA Multiple Sclerosis Drugs Market Overview
• 24.2. USA Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Multiple Sclerosis Drugs Market

• 25.1. Canada Multiple Sclerosis Drugs Market Overview
• 25.2. Canada Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Multiple Sclerosis Drugs Market

• 26.1. South America Multiple Sclerosis Drugs Market Overview
• 26.2. South America Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Multiple Sclerosis Drugs Market

• 27.1. Brazil Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Multiple Sclerosis Drugs Market

• 28.1. Middle East Multiple Sclerosis Drugs Market Overview
• 28.2. Middle East Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Multiple Sclerosis Drugs Market

• 29.1. Africa Multiple Sclerosis Drugs Market Overview
• 29.2. Africa Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Multiple Sclerosis Drugs Market Competitive Landscape And Company Profiles

• 30.1. Multiple Sclerosis Drugs Market Competitive Landscape
• 30.2. Multiple Sclerosis Drugs Market Company Profiles
  • 30.2.1. Biogen Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Novartis International AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. F. Hoffmann-La Roche Ltd.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Bayer HealthCare LLC
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Pfizer Inc
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Multiple Sclerosis Drugs Market Competitive Benchmarking

32. Global Multiple Sclerosis Drugs Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Multiple Sclerosis Drugs Market

34. Multiple Sclerosis Drugs Market Future Outlook and Potential Analysis

• 34.1 Multiple Sclerosis Drugs Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Multiple Sclerosis Drugs Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Multiple Sclerosis Drugs Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer